Search Results for HPE7-M01 Official Study Guide 🐂 Test HPE7-M01 Engine Version ❎ HPE7-M01 Exam Certification Cost 📻 Search for { HPE7-M01 } and download exam materials for free through ▷ www.pdfvce.com ◁ 🦢New HPE7-M01 Exam Pass4sure

Sorry, but nothing matched your search terms. Please try again with some different keywords.

NPX372

NextPoint is developing NPX372, a novel T-cell engager designed to target B7-H7 in solid tumors, further expanding NextPoint’s multi-modal focus on the emerging B7-H7 axis in cancer therapy.

B7-H7-ADC:

NextPoint is developing a novel antibody-drug conjugate optimized to target B7-H7 on tumor cells.

B7-H7-CD3:

NextPoint is developing a novel and potent T cell engager targeting B7-H7 which is designed to activate a tumor-directed immune response.

Clinical-Stage Project:
NPX267

NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3 which blocks the interaction with B7-H7 to re-activate T and NK cells. NPX267 is being studied in patients with solid tumor malignancies in a Phase 1 clinical trial.

Clinical-Stage Project:
NPX887

NPX887 is an Fc-enhanced monoclonal IgG1 antibody that targets B7-H7 to block its immunosuppressive interaction with KIR3DL3 on T and NK cells while sparing the interaction with its stimulatory ligand, TMIGD2. NPX887 is being studied in patients with solid tumor malignancies in a phase 1 clinical trial.